Adaptate Biotherapeutics is an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Their exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.
Gamma Delta Therapeutics spun out Adaptate Biotherapeutics in 2019. Both companies have benefitted from the support of King’s College London, the Francis Crick Institute and what is now Cancer Research Horizons.
Case study: A new approach to cancer immunotherapy